| Literature DB >> 8912534 |
A Hagiwara1, T Takahashi, K Sawai, C Sakakura, H Tsujimoto, T Imanishi, M Ohgaki, J Yamazaki, S Muranishi, A Yamamoto, T Fujita.
Abstract
A new delivery formulation (5FU-MS) of 5-fluorouracil (5FU), 5FU incorporated in microspheres composed of poly(glycolide-co-lactide) matrix, has been developed for the treatment of peritoneal carcinomatosis, and is designed to slowly release the incorporated 5FU for 3 weeks. Intraperitoneal 5FU-MS distributed higher concentrations of 5FU to the intraperitoneal tissues, such as the omentum and the mesentery, for a longer period with lower blood plasma concentrations than did the aqueous 5FU solution in rats. In experiments using mice, the lethal toxicity, determined by the probit method, in 5FU-MS was reduced to less than half that in aqueous 5FU solution. We evaluated the therapeutic effects on peritoneal carcinomatosis induced by the intraperitoneal inoculation of B-16 PC melanoma cells. The therapeutic effects of 5FU-MS were enhanced when compared with both the equivalent doses and same toxicity doses of the aqueous 5FU solution.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8912534 PMCID： PMC2074786 DOI： 10.1038/bjc.1996.554
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640